Laupheim, Germany
Rentschler Biopharma, founded in 1927, stands as a prominent Contract Development and Manufacturing Organization (CDMO) focused on advancing biopharmaceuticals. With its headquarters in Laupheim, Germany, and operational presence in Milford, MA, USA, the company excels in process development, biopharmaceutical manufacturing, consulting, project management, and regulatory support.
Notably, Rentschler Biopharma played a pivotal role in supporting approximately 25% of all FDA-approved biologics in 2023. Its commitment to excellence is underpinned by a robust quality management system and a culture of operational excellence. Moreover, the company's decision to join the United Nations Global Compact in 2024 underscores its increasing focus on sustainable practices.
As a private, family-owned entity boasting about 1,400 employees, Rentschler Biopharma has not yet disclosed details regarding recent investments or investors. Positioned in the dynamic intersection of Biopharma, Biotechnology, and Manufacturing industries, it offers promising potential for investors seeking a partner committed to both quality and innovation.
